- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02891070
Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery
August 21, 2019 updated by: Baxter Healthcare Corporation
A Randomised Controlled Study to Evaluate the Efficacy and Safety of Fibrin Sealant, Vapour Heated, Solvent/Detergent Treated FS VH S/D 500 S-apr (Tisseel) Compared to DuraSeal Dural Sealant as an Adjunct to Sutured Dural Repair in Cranial Surgery.
The objective of this study is to evaluate the safety and efficacy of FS VH S/D 500 s-apr for use as an adjunct to sutured dural repair in cranial surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
224
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brno, Czechia, 62500
- University Hospital Brno
-
Brno, Czechia, 65691
- St. Anne's University Hospital Brno
-
Hradec Kralove, Czechia, 50005
- University Hospital Hradec Kralove
-
Ostrava, Czechia, 70852
- University Hospital Ostrava
-
Praha 5, Czechia, 15030
- Hospital Na Homolce
-
Praha 5 - Motol, Czechia, 15006
- University Hospital Motol
-
-
-
-
-
Leipzig, Germany, 04103
- University Hospital Leipzig
-
Munich, Germany, 81925
- Hospital Bogenhausen Municipal Hospital
-
Rostock, Germany, 18057
- University Hospital Rostock
-
-
-
-
-
Badalona, Spain, 08916
- University Hospital Germans Trias i Pujol
-
Barcelona, Spain, 08036
- Hospital Clinic i Provincial de Barcelona
-
Madrid, Spain, 28040
- University Hospital Foundation Jimenez Diaz
-
Madrid, Spain, 28041
- University Hospital 12 de Octubre
-
Palma de Mallorca, Spain, 07010
- University Hospital Son Espases
-
Valencia, Spain, 46014
- University General Hospital of Valencia
-
-
-
-
Illinois
-
Springfield, Illinois, United States, 62702
- Southern Illinois University School of Medicine
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01199
- Baystate Medical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Case Medical Center
-
Columbus, Ohio, United States, 43201
- The Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Temple University School of Medicine
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Houston Methodist Neurological Institute
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients undergoing craniotomy/craniectomy for pathological processes in the PF or ST region
- Patients must be willing and able to participate in the study and provide written IC before any protocol specific assessment is performed
- Patients must be willing to receive peri-operative antibiotic prophylaxis
- Female patients of childbearing potential must present with a negative serum pregnancy test, and must agree to employ adequate birth control measures [restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products] for the duration of their participation in the study
- Patients are willing and able to comply with the requirements of the protocol
Exclusion Criteria:
- Patients with a dural lesion from a recent surgery that still has the potential for CSF leakage
- Patients who had undergone chemotherapy treatment, excluding hormonal therapy, within 3 weeks prior to the planned procedure, or with chemotherapy scheduled within 7 days following surgery
- Patients with radiation therapy to the surgical site or standard fractionated radiation therapy scheduled within 7 days following surgery
- Patients with a previous craniotomy/craniectomy within 6 months prior to the study surgery
- Use of corticosteroids on a chronic basis (defined as daily use of corticosteroids for ≥8 weeks) for purposes other than decreasing the symptoms of systemic chemotherapy (unless if those steroids were discontinued 4 weeks prior to the planned surgery)
- Patients with a known hypersensitivity to the components of the IP or control (human fibrinogen, synthetic aprotinin, human albumin, human FXIII, tri sodium citrate, histidine, niacinamide, polysorbate 80, human thrombin, polyethylene glycol [PEG], trilysine amine)
- Patients with a known hypersensitivity to US Federal Drug & Cosmetic Blue #1 dye
- Evidence of an infection indicated by any one of the following: clinical examination supporting the diagnosis of infection, fever (temperature >100.7°F or 38.2°C), positive urine culture, positive blood culture, positive chest X ray consistent with pulmonary infection, or infection along the planned surgical path. A white blood cell (WBC) count of <20000 cells/µL is permitted if the patient is being treated with steroids in the absence of all other infection parameters
- Female patients of childbearing potential with a positive pregnancy test or intent to become pregnant during the clinical study period
- Female patients who are nursing
- Patients with exposure to another investigational drug or device clinical trial within 30 days prior to enrolment or anticipated in the 60-day Follow-up period
- Patients with severely altered renal function as confirmed by local laboratory reference ranges for serum creatinine and/or hepatic function (alanine aminotransferase [ALT], aspartate aminotransferase >3 × upper limit of normal [ULN])
- Patients who currently have or have had a compromised immune system (such as Acquired Immune Deficiency Syndrome [AIDS]) or autoimmune disease, or were on chronic immunosuppressant agents
- Patients with uncontrolled diabetes as evidenced by the institution's standard of care (glycated haemoglobin [HbA1c] >7%, blood glucose, etc.)
- Patients with traumatic injuries to the head
- Patients with dural injury during craniotomy/craniectomy that cannot be eliminated by widening the craniotomy/craniectomy to recreate the native dural cuff
- Patients requiring surgical approaches that would not allow sutured dural closure such as trans-sphenoidal or translabyrinthine/-petrosal/-mastoid. Superficial penetration of mastoid air cells is allowed
- Patients with hydrocephalus, except occlusive hydrocephalus caused by PF pathology or incompletely open cerebrospinal fluid pathways, to be treated during surgical procedure
- Existing CSF (ventricular, etc.) drains, Cushing/Dandy cannulation, or Burr holes which damage the dura
- Patients with confined bony structures where nerves are present and neural compression may result due to swelling
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FS VH S/D 500 s-apr
FS VH S/D 500 s-apr (Tisseel), single use treatment, intraoperative
|
Other Names:
|
Active Comparator: DuraSeal Dural Sealant
DuraSeal Dural Sealant, single use treatment, intraoperative
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With No CSF Leak During and After Surgery
Time Frame: Day 0 (Intra-operative) to Day 30 (+/-3 days) post-operative
|
Participants who have no intra-operative CSF leak from dural repair after up to two applications during Valsalva maneuver (25 cm H2O for up to 5 - 10 seconds), or post-operative CSF leak within 30 (+3) days post-operatively.
The Valsalva maneuver was performed by the anaesthesiologist to increase the intra-thoracic pressure (e.g., by increasing the positive end-expiratory pressure or by giving a large tidal volume and holding the inflating pressure) to approximately 25 cm H2O, constantly for up to 5 - 10 seconds to transiently elevate the intracranial pressure and test for any CSF leaks.
The suture line was to be watertight after up to two product/control applications and Valsalva maneuvers.
|
Day 0 (Intra-operative) to Day 30 (+/-3 days) post-operative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With no Intra-operative CSF Leaks Following Final Valsalva Maneuver
Time Frame: Day 0 (Intra-operative)
|
Assessment of whether the suture line was not watertight causing CSF leaks after up to two product/control applications and Valsalva maneuvers.
|
Day 0 (Intra-operative)
|
Number of Participants With CSF Leaks Within 30 (+3) Days Post-operatively
Time Frame: Day 0 (Intra-operative) to Day 30 (+/-3 days) post-operative
|
Cerebrospinal fluid leak was defined as any overt flow, seepage, weeping, or sweating of CSF through the dura suture line, regardless of volume.
All post-operative CSF leaks were primarily diagnosed based on a detailed history and physical examination, including neurological examination.
Although not standard of care post-operatively, imaging tests such as computed tomography/magnetic resonance imaging (MRI) were considered if there was a high clinical suspicion of a CSF leak.
|
Day 0 (Intra-operative) to Day 30 (+/-3 days) post-operative
|
Duration in Surgery (Minutes)
Time Frame: Day 0 (intra-operatively)
|
Patients undergoing elective cranial surgery for the treatment of a pathological condition (e.g., benign/malignant tumours, vascular malformations, or Chiari type 1 malformations) specifically located in the posterior fossa (PF) or supratentorial (ST) regions.
|
Day 0 (intra-operatively)
|
Time From Dural Closure (Application of IP) Until End of Surgery
Time Frame: Day 0 (Intra-operatively)
|
Suture closure techniques include continuous simple, continuous locked, interrupted.
|
Day 0 (Intra-operatively)
|
Length of Stay in Hospital (Days).
Time Frame: Day 0 to Day 60 (Study Completion)
|
Days in hospital calculation is Day 0 - Discharge.
|
Day 0 to Day 60 (Study Completion)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Qing Li, MD, PhD, Baxter Healthcare
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 11, 2016
Primary Completion (Actual)
August 22, 2018
Study Completion (Actual)
August 22, 2018
Study Registration Dates
First Submitted
September 1, 2016
First Submitted That Met QC Criteria
September 1, 2016
First Posted (Estimate)
September 7, 2016
Study Record Updates
Last Update Posted (Actual)
September 10, 2019
Last Update Submitted That Met QC Criteria
August 21, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3599-001
- 2015-005535-40 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebrospinal Fluid Leak
-
The Cleveland ClinicCompletedCerebrospinal Fluid Drainage Catheter
-
Kuros Biosurgery AGCompletedCerebrospinal Fluid LeakageGermany, Hungary
-
TakedaCompletedCerebrospinal Fluid LeaksAustria, Belgium, France, Germany, Greece, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden
-
University of ZurichCompletedCerebrospinal Fluid LeakageSwitzerland
-
University of North Carolina, Chapel HillUNC Medical AlumniCompletedCerebrospinal Fluid DrainageUnited States
-
Integra LifeSciences CorporationMedtronic - MITGCompletedCerebrospinal Fluid Leakage, SubduralUnited States
-
Insel Gruppe AG, University Hospital BernTerminated
-
Stanford UniversityWithdrawn
-
Assiut UniversityNot yet recruitingImaging of Active CSF Rhinorrhea
Clinical Trials on FS VH S/D 500 s-apr
-
Baxter Healthcare CorporationCompletedAdjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)United States
-
Baxter Healthcare CorporationCompletedFace-lift | Facial RhytidectomyUnited States
-
Baxter Healthcare CorporationBaxter Innovations GmbHCompleted
-
Baxter Healthcare CorporationCompletedDura Defects | Pathological Processes in the Posterior FossaUnited States, Canada
-
Baxter Healthcare CorporationCompleted
-
Baxter Healthcare CorporationCompletedCardiopulmonary Bypass | Sternotomy | Cardiac Surgery Requiring Cardiopulmonary Bypass and Median SternotomyUnited States
-
Baxter Healthcare CorporationCompletedBreast Cancer | Lumpectomy | Mastectomy Plus Axillary Lymph Node Dissection | Lymphatic LeakageGermany, Austria, France, Italy
-
Baxter Healthcare CorporationCompletedHemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft ProsthesesUnited States
-
Al-Rasheed University CollegeCompleted
-
Entegrion, Inc.CompletedCoagulation DefectsUnited States